MX364483B - Derivado de azol benceno. - Google Patents
Derivado de azol benceno.Info
- Publication number
- MX364483B MX364483B MX2015009655A MX2015009655A MX364483B MX 364483 B MX364483 B MX 364483B MX 2015009655 A MX2015009655 A MX 2015009655A MX 2015009655 A MX2015009655 A MX 2015009655A MX 364483 B MX364483 B MX 364483B
- Authority
- MX
- Mexico
- Prior art keywords
- diseases including
- xanthine oxidase
- diseases
- salt
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto representado por la fórmula (I) o una de sus sales aceptables desde el punto de vista farmacéutico o un producto farmacéutico o una composición farmacéutica que contiene el mismo como principio activo, que tiene una excelente actividad inhibidora de xantina oxidasa y es útil como un agente terapéutico o un agente preventivo para enfermedades asociadas con xantina oxidasa tales como gota, hiperuricemia, síndrome de lisis tumoral, cálculos urinarios, hipertensión, dislipidemia, diabetes, enfermedades cardiovasculares tales como ateroesclerosis o insuficiencia cardíaca, enfermedades renales tales como nefropatía diabética, enfermedades respiratorias tales como enfermedades pulmonares obstructivas crónicas, enfermedades de inflamación intestinal o enfermedades autoinmunes. Fórmula Química 1 (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013017167 | 2013-01-31 | ||
| PCT/JP2014/052154 WO2014119681A1 (ja) | 2013-01-31 | 2014-01-30 | アゾールベンゼン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015009655A MX2015009655A (es) | 2015-12-07 |
| MX364483B true MX364483B (es) | 2019-04-26 |
Family
ID=51262388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009655A MX364483B (es) | 2013-01-31 | 2014-01-30 | Derivado de azol benceno. |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9388174B2 (es) |
| EP (1) | EP2952513B1 (es) |
| JP (1) | JP5734532B2 (es) |
| KR (1) | KR102199258B1 (es) |
| CN (1) | CN104968662B (es) |
| AR (1) | AR095098A1 (es) |
| AU (1) | AU2014213396B2 (es) |
| BR (1) | BR112015018033B1 (es) |
| CA (1) | CA2897928C (es) |
| CL (1) | CL2015002117A1 (es) |
| CY (1) | CY1122015T1 (es) |
| DK (1) | DK2952513T3 (es) |
| ES (1) | ES2744817T3 (es) |
| HK (1) | HK1215806A1 (es) |
| HR (1) | HRP20191554T1 (es) |
| HU (1) | HUE047028T2 (es) |
| IL (2) | IL239940B (es) |
| LT (1) | LT2952513T (es) |
| MA (1) | MA38295B1 (es) |
| ME (1) | ME03516B (es) |
| MX (1) | MX364483B (es) |
| MY (1) | MY181731A (es) |
| NZ (1) | NZ709407A (es) |
| PE (1) | PE20151329A1 (es) |
| PH (2) | PH12015501640A1 (es) |
| PL (1) | PL2952513T3 (es) |
| PT (1) | PT2952513T (es) |
| RS (1) | RS59371B1 (es) |
| RU (1) | RU2641891C2 (es) |
| SA (1) | SA515360829B1 (es) |
| SG (1) | SG11201505993PA (es) |
| SI (1) | SI2952513T1 (es) |
| TW (1) | TWI606048B (es) |
| UA (1) | UA117124C2 (es) |
| WO (1) | WO2014119681A1 (es) |
| ZA (1) | ZA201505240B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505953TA (en) | 2013-01-31 | 2015-08-28 | Vertex Pharma | Pyridone amides as modulators of sodium channels |
| DK3080134T3 (en) | 2013-12-13 | 2018-10-22 | Vertex Pharma | PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS |
| JP6134072B2 (ja) * | 2014-07-30 | 2017-05-24 | 帝人ファーマ株式会社 | キサンチンオキシダーゼ阻害薬 |
| NZ729045A (en) * | 2014-07-30 | 2022-05-27 | Teijin Pharma Ltd | Crystal of azole benzene derivative |
| RS58315B1 (sr) | 2014-07-30 | 2019-03-29 | Teijin Pharma Ltd | Derivat azol benzena i njegov kristal |
| EP3417858B8 (en) | 2016-02-19 | 2020-12-30 | National University Corporation Tottori University | Therapeutic or prophylactic drug for dementia |
| CN109982697A (zh) | 2016-11-28 | 2019-07-05 | 帝人制药株式会社 | 糖尿病性肾病的治疗药或预防药 |
| KR20200006128A (ko) | 2017-05-16 | 2020-01-17 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
| US11529337B2 (en) | 2018-02-12 | 2022-12-20 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| AU2020397059A1 (en) | 2019-12-06 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| IL308953A (en) | 2021-06-04 | 2024-01-01 | Vertex Pharma | N-Hydroalkyl(Hetero)Aryl)Tetrahydrofuran Carboxamides as Natrene Channel Modulators |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122008000051I1 (de) | 1990-11-30 | 2009-02-05 | Teijin Ltd | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
| US5843969A (en) * | 1995-04-07 | 1998-12-01 | Teijin Limited | Protecting agent for organ or tissue |
| SK282425B6 (sk) * | 1995-04-21 | 2002-01-07 | Neurosearch A/S | Benzimidazolové zlúčeniny, farmaceutické zmesi obsahujúce tieto zlúčeniny a použitie týchto zlúčenín |
| JP2002105067A (ja) | 2000-09-28 | 2002-04-10 | Teijin Ltd | ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
| KR20080066938A (ko) | 2005-10-07 | 2008-07-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물 |
| WO2008126770A1 (ja) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体の製造方法 |
| US8227500B2 (en) | 2007-04-11 | 2012-07-24 | Kissei Pharmaceutical Co., Ltd. | 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same |
| WO2010018458A2 (en) | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
| WO2010128163A2 (en) | 2009-05-08 | 2010-11-11 | Pike Pharma Gmbh | Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication |
| EP2536699A2 (en) | 2010-02-19 | 2012-12-26 | Cadila Healthcare Limited | Substantially pure salts of febuxostat and processes for preparation thereof |
| EP2563768A4 (en) | 2010-04-29 | 2013-07-31 | Reddys Lab Ltd Dr | MANUFACTURE OF FEBUXOSTAT |
-
2014
- 2014-01-29 TW TW103103559A patent/TWI606048B/zh active
- 2014-01-30 CN CN201480006601.1A patent/CN104968662B/zh active Active
- 2014-01-30 PE PE2015001576A patent/PE20151329A1/es active IP Right Grant
- 2014-01-30 BR BR112015018033-7A patent/BR112015018033B1/pt active IP Right Grant
- 2014-01-30 EP EP14746209.7A patent/EP2952513B1/en active Active
- 2014-01-30 RU RU2015132105A patent/RU2641891C2/ru active
- 2014-01-30 LT LT14746209T patent/LT2952513T/lt unknown
- 2014-01-30 MY MYPI2015702266A patent/MY181731A/en unknown
- 2014-01-30 MX MX2015009655A patent/MX364483B/es active IP Right Grant
- 2014-01-30 US US14/442,752 patent/US9388174B2/en active Active
- 2014-01-30 UA UAA201507650A patent/UA117124C2/uk unknown
- 2014-01-30 RS RSP20191244 patent/RS59371B1/sr unknown
- 2014-01-30 PT PT14746209T patent/PT2952513T/pt unknown
- 2014-01-30 PL PL14746209T patent/PL2952513T3/pl unknown
- 2014-01-30 ES ES14746209T patent/ES2744817T3/es active Active
- 2014-01-30 DK DK14746209.7T patent/DK2952513T3/da active
- 2014-01-30 SG SG11201505993PA patent/SG11201505993PA/en unknown
- 2014-01-30 NZ NZ70940714A patent/NZ709407A/en not_active IP Right Cessation
- 2014-01-30 AU AU2014213396A patent/AU2014213396B2/en active Active
- 2014-01-30 CA CA2897928A patent/CA2897928C/en active Active
- 2014-01-30 JP JP2014557920A patent/JP5734532B2/ja active Active
- 2014-01-30 SI SI201431281T patent/SI2952513T1/sl unknown
- 2014-01-30 AR ARP140100314A patent/AR095098A1/es unknown
- 2014-01-30 WO PCT/JP2014/052154 patent/WO2014119681A1/ja active Application Filing
- 2014-01-30 HU HUE14746209A patent/HUE047028T2/hu unknown
- 2014-01-30 KR KR1020157019782A patent/KR102199258B1/ko active IP Right Grant
- 2014-01-30 ME MEP-2019-262A patent/ME03516B/me unknown
- 2014-01-30 MA MA38295A patent/MA38295B1/fr unknown
-
2015
- 2015-07-14 IL IL239940A patent/IL239940B/en active IP Right Grant
- 2015-07-21 ZA ZA2015/05240A patent/ZA201505240B/en unknown
- 2015-07-23 PH PH12015501640A patent/PH12015501640A1/en unknown
- 2015-07-29 SA SA515360829A patent/SA515360829B1/ar unknown
- 2015-07-29 CL CL2015002117A patent/CL2015002117A1/es unknown
-
2016
- 2016-04-01 HK HK16103729.4A patent/HK1215806A1/zh unknown
-
2018
- 2018-02-05 PH PH12018500261A patent/PH12018500261A1/en unknown
- 2018-06-05 IL IL259824A patent/IL259824B/en active IP Right Grant
-
2019
- 2019-08-28 HR HRP20191554 patent/HRP20191554T1/hr unknown
- 2019-09-10 CY CY20191100944T patent/CY1122015T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500261A1 (en) | Azole benzene derivative | |
| BR112012033715A2 (pt) | inibidores de quinase de regulação de sinal de apoptose. | |
| PH12015501037A1 (en) | Pyridine derivative | |
| NZ739339A (en) | Apoptosis signal-regulating kinase inhibitor | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| WO2012149157A3 (en) | Heterocyclic compounds for the inhibition of pask | |
| WO2011084991A3 (en) | Fluorinated hdac inhibitors and uses thereof | |
| MX2014001946A (es) | Inhibidores del canal de potasio medularmente externo renal. | |
| WO2014099633A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
| WO2012117000A8 (en) | 3-amino-pyridines as gpbar1 agonists | |
| MY161001A (en) | Tetrahydrocarboline Derivative | |
| EA025158B9 (ru) | Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения | |
| WO2012119046A3 (en) | Heterocyclic compounds for the inhibition of pask | |
| JP2013166781A5 (es) | ||
| WO2012094462A3 (en) | Heterocyclic compounds for the inhibition of pask | |
| WO2008116663A3 (en) | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | |
| WO2008087461A3 (en) | Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis | |
| NO20085375L (no) | Nitrerte hetrosykliske forbindelser som endotelin-reseptorantagonist | |
| NZ609596A (en) | Cyclohexane derivative compound | |
| CY1120672T1 (el) | Παραγωγο πυραζολης | |
| BR112014018226A8 (pt) | Derivados de pirimidooxazocina como inibidores de mtor | |
| TN2012000093A1 (en) | Therapeutic agent for anxiety disorders | |
| PH12016502223A1 (en) | Pyrazine derivatives | |
| AR101364A1 (es) | Derivado de ácido azolcarboxílico | |
| JP2014201568A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |